systemic immunosuppression because they were either too old and infirm (patients 1 and 2) or they had been unable to tolerate it (patients 3-5). Interferon alfa-2b was given in doses of 1.5 x 106 IU twice weekly for 3 weeks then weekly for another 3 weeks for a mean total dose of 12.8 (range 9-16) x 106 IU. After topical anaesthetic had been given, the drug was injected in a volume of 0.2 ml beneath the posterior bulbar conjunctiva, preferably in an area uninvolved by symblepharon. Only the eye that displayed the more advanced disease was treated in each patient, the other eye serving as a control. Table 1 shows the results of a pretreatment conjunctival biopsy and the pre-and posttreatment (most recent) OCP scores7 for each patient. This OCP grading scheme, devised by us, takes into account inflammation, acuity, and the sequelae of both dryness and fibrosis. Patients 1 and 2 had OCP related to topical glaucoma medication8 which had already been discontinued. The scores of the treated eyes were unchanged in two patients and improved in three. Interestingly, no progression was found in untreated eyes. All patients reported a gradual easing of their symptoms of chronic ocular discomfort in the treated eye during the months after treatment. No significant adverse events were found, nor has any patient required subsequent treatment in either eye apart from occasional topical steroid preparations. COMMENT The mechanism of action of IFNa against OCP is uncertain. The lack of progression in untreated eyes may be simply because the disease was less active in that eye, as it was in each of our cases, but it also raises the possibility of an effect of IFNa on the systemic immune response. This would be consistent with ability of IFNax to downregulate class II MHC antigen expression3 resulting in a reduced antigen load visible to immune surveillance mechanisms. The greater effect in the treated eye, however, suggests that local factors, such as its antifibrotic effect, might also be important.
When combined with the data from a previous study,9 these results show that subconjunctival IFNa as we administered it appears to be relatively safe in humans. Systemic problems are very unlikely at this low dose, as are local side effects. Although systemic IFNa has occasionally been associated with the development of autoimmune disease, no such ocular association has ever been described. Similarly, we have not found any evidence of retinal vascular disease in our patients.
While these results are encouraging with respect to efficacy, the number of patients is too small to allow any firm conclusions to be drawn. We recommend that interferon alfa be used There was no afferent pupillary defect. Motility was normal, but there was a 15 dioptre exotropia in the right eye. Confrontation visual fields were intact in both eyes. Slit-lamp examination was remarkable for a narrow band of corneal thinning inferiorly in the right eye with central bulging above the thinned zone and an area of normal thickness between the thinned section and the limbus (Fig 1) . Faint vertical stromal striae were present in the right eye. No iron lines, lipid deposition, or vascularisation were present in the cornea in the right eye. The left cornea appeared normal, without any trace of iron line, striae,
